1. Home
  2. ROMA vs SGMO Comparison

ROMA vs SGMO Comparison

Compare ROMA & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

N/A

Current Price

$2.32

Market Cap

148.9M

Sector

Finance

ML Signal

N/A

Logo Sangamo Therapeutics Inc.

SGMO

Sangamo Therapeutics Inc.

HOLD

Current Price

$0.45

Market Cap

155.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROMA
SGMO
Founded
2018
1995
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
148.9M
155.1M
IPO Year
2024
2000

Fundamental Metrics

Financial Performance
Metric
ROMA
SGMO
Price
$2.32
$0.45
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$4.71
AVG Volume (30 Days)
3.3K
9.2M
Earning Date
12-26-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,568,345.00
$32,875,000.00
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.21
N/A
52 Week Low
$0.58
$0.38
52 Week High
$4.66
$2.84

Technical Indicators

Market Signals
Indicator
ROMA
SGMO
Relative Strength Index (RSI) 41.27 43.51
Support Level $2.23 $0.49
Resistance Level $2.51 $0.51
Average True Range (ATR) 0.11 0.04
MACD -0.02 0.01
Stochastic Oscillator 41.70 31.04

Price Performance

Historical Comparison
ROMA
SGMO

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Share on Social Networks: